AU2003251709A1 - Diagnostic and therapeutic use of proteolipid protein for alzheimer's disease - Google Patents
Diagnostic and therapeutic use of proteolipid protein for alzheimer's diseaseInfo
- Publication number
- AU2003251709A1 AU2003251709A1 AU2003251709A AU2003251709A AU2003251709A1 AU 2003251709 A1 AU2003251709 A1 AU 2003251709A1 AU 2003251709 A AU2003251709 A AU 2003251709A AU 2003251709 A AU2003251709 A AU 2003251709A AU 2003251709 A1 AU2003251709 A1 AU 2003251709A1
- Authority
- AU
- Australia
- Prior art keywords
- alzheimer
- diagnostic
- disease
- therapeutic use
- proteolipid protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 102000016202 Proteolipids Human genes 0.000 title 1
- 108010010974 Proteolipids Proteins 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40413102P | 2002-08-19 | 2002-08-19 | |
| EP02018567.4 | 2002-08-19 | ||
| US60/404,131 | 2002-08-19 | ||
| EP02018567 | 2002-08-19 | ||
| PCT/EP2003/009130 WO2004019044A1 (fr) | 2002-08-19 | 2003-08-18 | Utilisation diagnostique et therapeutique de la proteine proteolipide contre la maladie d'alzheimer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2003251709A1 true AU2003251709A1 (en) | 2004-03-11 |
Family
ID=31947888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003251709A Abandoned AU2003251709A1 (en) | 2002-08-19 | 2003-08-18 | Diagnostic and therapeutic use of proteolipid protein for alzheimer's disease |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2003251709A1 (fr) |
| WO (1) | WO2004019044A1 (fr) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0685558A1 (fr) * | 1994-05-27 | 1995-12-06 | Bayer Ag | Animaux transgéniques déficients en protéine protéolipidique et méthode d'obtention de tels animaux |
-
2003
- 2003-08-18 AU AU2003251709A patent/AU2003251709A1/en not_active Abandoned
- 2003-08-18 WO PCT/EP2003/009130 patent/WO2004019044A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004019044A1 (fr) | 2004-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001249835A1 (en) | Diagnosis and treatment of alzheimer's disease | |
| AU2003220096A1 (en) | Methods for alzheimer's disease treatment and cognitive enhancement | |
| AU2003206413A1 (en) | Substituted amino carboxamides for the treatment of alzheimer's disease | |
| SI1334091T1 (sl) | Derivati tioflavina in njihova uporaba pri diagnozi in terapiji pri Alzheimerjevi bolezni | |
| EP1392287B8 (fr) | Usage de dérivés de l'azétidinone pour le traitement de la maladie d' Alzheimer. | |
| AU2003277010A1 (en) | A method and system for detecting the effects of alzheimer's disease in the human retina | |
| AU2002335794A1 (en) | Allylamides useful in the treatment of alzheimer's disease | |
| AU2002212471A1 (en) | Peptides for use in the treatment of alzheimer's disease | |
| AU2003268295A8 (en) | "diagnosis and treatment of infertility" | |
| AU2002222108A1 (en) | Diagnosis and treatment of alzheimer's disease | |
| AU5550800A (en) | Diagnosis and treatment of alzheimer's disease | |
| AU2003303141A1 (en) | Hydroxypropyl amides for the treatment of alzheimer's disease | |
| AU2003248660A1 (en) | Treatment of vascular dysfunction and alzheimer's disease | |
| AU2001289834A1 (en) | Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders | |
| AU2003273310A1 (en) | Substituted aminoethers for the treatment of alzheimer's disease | |
| AU2003260301A1 (en) | Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases | |
| PL377110A1 (pl) | Zapobieganie i leczenie choroby Alzheimera | |
| AU2002352054A1 (en) | "in vitro" diagnostic method for diseases affecting human or animal tissues | |
| AU2003279312A1 (en) | Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases | |
| AU2003288127A1 (en) | DIAGNOSTIC AND THERAPEUTIC USE OF H-Rev107 PROTEIN FOR ALZHEIMER DISEASE | |
| AU2003251709A1 (en) | Diagnostic and therapeutic use of proteolipid protein for alzheimer's disease | |
| IL172213A0 (en) | Compounds useful in the therapy of alzheimer's disease and formulations containing them | |
| AU2003289859A1 (en) | Diagnostic and therapeutic use of arl7 for alzheimer's disease | |
| AU2003286530A1 (en) | Substituted peptides useful in the treatment of alzheimer's disease | |
| AU2002312797A1 (en) | Peptide for the diagnosis and therapy of alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |